Ubrogepant Found Safe and Effective for Acute Migraine Symptoms in Trials

A significantly higher proportion of patients treated with an oral calcitonin gene–related peptide receptor antagonist achieved freedom from pain and relief of their most harmful migraine-associated symptom at two hours after treatment compared with placebo, according to two new studies.